Predictors of all-cause hospitalizations in patients with MS included increased age, presence of a comorbidity, and having a history of hospital admissions.
A recent case report examined the adverse effects of alemtuzumab in a patient with relapsing remitting multiple sclerosis.
The mechanism by which it exerts therapeutic effects in MS is unknown but may involve the reduction of lymphocyte migration into the central nervous system.
The New Drug Application for ponesimod has been submitted to the Food and Drug Administration for the treatment of relapsing multiple sclerosis.
Age-dependent differences seen for clinical outcomes in response to disease-modifying therapy.
Extracted features from three sensors correlate with physician-rated, patient-reported disability status.
Serum NfL levels are indicative of ongoing neuroinflammation and may be predictive of neurodegeneration in patients with early MS.
The FDA has accepted for Priority Review the supplemental Biologics License Application (sBLA) for ofatumumab (Novartis) for the treatment of relapsing forms of multiple sclerosis (RMS) in adults.
A network of gut bacteria species may be associated with host genetic factors that increase susceptibility to multiple sclerosis.
More patients with early relapsing-remitting multiple sclerosis (RRMS) treated with natalizumab experienced confirmed disability improvement than disability worsening.
